Cnto 1275
Primary Biliary Cirrhosis
Janssen Research & Development, LLCPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Primary Biliary Cirrhosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
URSODEOXYCHOLIC ACID Xijing Hospital of Digestive Diseases | Phase 4 | A |
Saroglitazar Zydus Therapeutics Inc. | Phase 3 | BB |
Fenofibrate Xijing Hospital of Digestive Diseases | Phase 3 | BB |
cs0159 Cascade Pharmaceuticals, Inc | Phase 3 | BB |
Mbx-8025 Gilead Sciences | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Cnto 1275 is also rated in:
diarrhea, glucose-stimulated secretory, with common variable immunodeficiencyDormant
CCC
Indicative ·
52 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →